BioLine RX (Israel) Buy Hold or Sell Recommendation
| BLRX Stock | ILS 7.10 0.40 5.33% |
Assuming the 90 days trading horizon and your complete indifference towards market risk, our recommendation regarding BioLine RX is 'Buy'. Macroaxis provides BioLine RX buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BLRX positions.
Check out BioLine RX Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as BioLine and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards BioLine RX. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
BioLine |
Execute BioLine RX Buy or Sell Advice
The BioLine recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioLine RX. Macroaxis does not own or have any residual interests in BioLine RX or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioLine RX's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
BioLine RX Trading Alerts and Improvement Suggestions
| BioLine RX generated a negative expected return over the last 90 days | |
| BioLine RX has high historical volatility and very poor performance | |
| Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
BioLine RX Returns Distribution Density
The distribution of BioLine RX's historical returns is an attempt to chart the uncertainty of BioLine RX's future price movements. The chart of the probability distribution of BioLine RX daily returns describes the distribution of returns around its average expected value. We use BioLine RX price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioLine RX returns is essential to provide solid investment advice for BioLine RX.
| Mean Return | -1.65 | Value At Risk | -9.03 | Potential Upside | 5.19 | Standard Deviation | 6.20 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioLine RX historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioLine RX Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioLine RX or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioLine RX's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioLine stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.69 | |
β | Beta against Dow Jones | 0.24 | |
σ | Overall volatility | 6.20 | |
Ir | Information ratio | -0.29 |
BioLine RX Volatility Alert
BioLine RX is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BioLine RX's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BioLine RX's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.BioLine RX Fundamentals Vs Peers
Comparing BioLine RX's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioLine RX's direct or indirect competition across all of the common fundamentals between BioLine RX and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioLine RX or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioLine RX's fundamental indicators could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioLine RX to competition |
| Fundamentals | BioLine RX | Peer Average |
| Return On Equity | -0.37 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Current Valuation | (13.02 M) | 16.62 B |
| Shares Outstanding | 922.87 M | 571.82 M |
| Shares Owned By Insiders | 0.25 % | 10.09 % |
| Shares Owned By Institutions | 0.10 % | 39.21 % |
| Price To Book | 0.77 X | 9.51 X |
| EBITDA | (25.37 M) | 3.9 B |
| Net Income | (27.05 M) | 570.98 M |
| Cash And Equivalents | 40.61 M | 2.7 B |
| Cash Per Share | 0.28 X | 5.01 X |
| Total Debt | 10.69 M | 5.32 B |
| Debt To Equity | 23.20 % | 48.70 % |
| Current Ratio | 5.12 X | 2.16 X |
| Book Value Per Share | 0.08 X | 1.93 K |
| Cash Flow From Operations | (23.57 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Target Price | 3.0 | |
| Number Of Employees | 38 | 18.84 K |
| Beta | 1.27 | -0.15 |
| Market Capitalization | 135.72 M | 19.03 B |
| Total Asset | 81.39 M | 29.47 B |
| Retained Earnings | (163 M) | 9.33 B |
| Working Capital | 43 M | 1.48 B |
| Current Asset | 46 M | 9.34 B |
| Current Liabilities | 3 M | 7.9 B |
| Z Score | 4.4 | 8.72 |
| Net Asset | 81.39 M |
BioLine RX Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioLine . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BioLine RX Buy or Sell Advice
When is the right time to buy or sell BioLine RX? Buying financial instruments such as BioLine Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioLine RX in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.